AI Optics’ Sentinel Camera gains FDA 510(k) clearance

News
Article

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

AI Optics' portable Sentinel Camera Image credit: AI Optics

AI Optics' portable Sentinel Camera Image credit: AI Optics

AI Optics, an AI-focused medical device company, has received FDA 510(k) clearance for its Sentinel Camera, a handheld retinal imaging system.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye. According to the company, this eliminates the need for some patients to visit an eye specialist’s office. Additionally, the Sentinel Camera supports DICOM-compliant image formats, allowing integration with Electronic Health Record (EHR) systems.

"The fact that this device provides truly immediate results is a massive differentiator," Matthew Alpert, OD, president of TEC Eye Consortium, told AI Optics.2 "No busy clinician has the time to wait for results. On top of that, it introduces an incremental revenue stream, differentiates your practice, and improves HEDIS scores.”

Luke Moretti, co-founder and CEO of AI Optics, commented on the device and clearance in a press release from the company.

"Our vision with the Sentinel Camera is to eliminate barriers to retinal screening and ensure that every patient who needs screening has access," said Moretti "This FDA clearance not only validates our significant progress to breaking down screening barriers but also sets the stage for our future AI-powered screening solutions, which will integrate seamlessly with the Sentinel Camera to deliver unparalleled accessibility and efficiency in retinal disease detection."

In addition to the clearance, AI Optics is developing AI-based retinal screening software for future integration. The company aims to provide a comprehensive end-to-end solution for detecting retinal diseases such as diabetic retinopathy, glaucoma, and macular degeneration.

AI Optics is also collaborating with NYU Langone Health with the goal of advancing the accessibility and implementation of retinal screening technology. According to the company, this clearance “marks a pivotal step in this journey, enabling the integration of high-quality, portable imaging into diverse healthcare environments.”

References:
  1. AI Optics Receives FDA Clearance, Increasing Patient Access to Retinal Screening. Press Release. Published January 28, 2025. Accessed January 28, 2025.https://investors.apellis.com/news-releases/news-release-details/apellis-receives-approval-syfovrer-pegcetacoplan-australia
  2. AI-powered retinal screening for optometry practices. AI Optics. Accessed February 6, 2025. https://www.aioptics.ai/optometry

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.